 Adefovir
(Hepsera)
EMERGENCE
OF DUAL-RESISTANCE HBV MUTATIONS TO ADEFOVIR-DIPIVOXIL AND LAMIVUDINE IN
A HEPATITIS B PATIENT WITH COMBINATION THERAPY FOR ADEFOVIR-RESISTANCE
SY
Kwon. Abstract 740.
SAFETY AND EFFICACY OF ADEFOVIR DIPIVOXIL
IN PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B UNDERGOING LIVER TRANSPLANTATION.
E
Schiff. Abstract 2
(Oral).  TWO-STATE MODELING OF VIROLOGICAL AND BIOCHEMICAL EFFICACY PLUS LIVER
BIOPSIES DEMONSTRATE EFFICACY OF ADEFOVIR DIPIVOXIL IN HBEAG-NEGATIVE CHRONIC
HEPATITIS B OVER FOUR OR FIVE YEARS
S
Hadziyannis. Abstract 494. THE
IMPROVED THERAPEUTIC EFFECTS OF ADEFOVIR DIPIVOXIL IN PATIENTS WITH HBE-AG-NEGATIVE
CHRONIC HEPATITIS B OFFSET AGAINST ITS INCREASED COST COMPARED TO LAMIVUDINE
M Buti. Abstract 485. FINAL ANALYSIS OF VIROLOGICAL OUTCOMES AND RESISTANCE DURING 5-YEARS
OF ADEFOVIR DIPIVOXIL MONOTHERAPY IN HBEAG-NEGATIVE PATIENTS
K Borroto-Esoda. Abstract 483. DURABILITY OF HBEAG SEROCONVERSION FOLLOWING ADEFOVIR DIPIVOXIL TREATMENT
FOR CHRONIC HEPATITIS B (CHB)
T T Chang. Abstract 503.
TREATMENT
WITH ADEFOVIR ALONE OR IN COMBINATION WITH LAMIVUDINE IN CHRONIC HEPATITIS B LAMIVUDINE-RESISTANT
PATIENTS: RESULTS AFTER TWO YEARS.
V Barbon. Abstract 480. FINAL ANALYSIS OF VIROLOGICAL OUTCOMES AND RESISTANCE DURING 5-YEARS
OF ADEFOVIR DIPIVOXIL MONOTHERAPY IN HBEAG-NEGATIVE PATIENTS
K. Borroto-Esoda. Abstract 483. EFFICACY AND SAFETY OF 2 YEARS ADEFOVIR DIPIVOXIL (ADV) IN CHINESE
PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B (CHB).
M D Zeng. Abstract 496. VIRAL RESISTANCE OCCURS VERY COMMONLY DURING LONG-TERM ADEFOVIR THERAPY
IN LAMIVUDINE-RESISTANT PATIENTS WITH GENOTYPE C HEPATITIS B VIRUS
Y-S.
Lee. Abstract 500 . PRIMARY ADEFOVIR RESISTANCE
MUTATIONS IN PATIENTS WITH YMDD MUTATION AND RESISTANCE TO LAMIVUDINE: THE INCIDENCE
AND CLINICAL COURSE
J. H. Lee. Abstract 467. HBV QUASISPECIES SELECTED DURING LAMIVUDINE TREATMENT MAY CONTRIBUTE
TO ADEFOVIR DIPIVOXIL RESISTANCE
F
Moriconi. Abstract 504. VIRAL RESISTANCE TO ADEFOVIR THERAPY RESULTS FROM REAPPEARED WILD
TYPE HEPATITIS B VIRUS IN MAJORITY OF PATIENTS WITH YMDD MUTANTS
S H Ryu. Abstract 510. PRIMARY RESISTANCE OF A NOVEL HEPATITIS B VIRUS VARIANT TO ADEFOVIR
O
Schildgen. Abstract
511. NON-RESPONSE AND RESISTANCE TO ADEFOVIR DIPIVOXIL IN CHRONIC HEPATITIS
B PATIENTS WITH LAMIVUDINE RESISTANCE
A Valdes.
Abstract 515. 
Entecavir
(Baraclude)
ENTECAVIR (ETV) DEMONSTRATES CONSISTENT RESPONSES THROUGHOUT BASELINE
DISEASE AND DEMOGRAPHIC SUBGROUPS FOR THE TREATMENT OF LAMIVUDINE-REFRACTORY HBEAG(+)
PATIENTS WITH CHRONIC HEPATITIS B
C Yurdaydin. Abstract 512. ENTECAVIR RESULTS IN
EARLY VIRAL LOAD REDUCTION IN CHRONIC HEPATITIS B PATIENTS WHO HAVE FAILED LAMIVUDINE
THERAPY: A RANDOMIZED, PLACEBO-CONTROLLED STUDY IN CHINA
G Yao. Abstract 518. EFFICACY AND SAFETY OF ENTECAVIR IN JAPANESE ADULT PATIENTS WITH INCOMPLETE
RESPONSE TO CURRENT LAMIVUDINE TREATMENT: A PHASE II CLINICAL TRIAL
Y Karino. Abstract 498. ENTECAVIR RESULTS IN CONTINUED VIROLOGIC AND BIOCHEMICAL IMPROVEMENT
AND HBEAG SEROCONVERSION THROUGH 96 WEEKS OF TREATMENT IN LAMIVUDINE-REFRACTORY,
HBEAG(+) CHRONIC HEPATITIS B PATIENTS (ETV-026)
C
Yurdaydin. Abstract 80.
ENTECAVIR IS SUPERIOR TO LAMIVUDINE FOR THE TREATMENT OF CHRONIC HEPATITIS
B (CHB): RESULTS OF A PHASE 3 CHINESE STUDY (ETV-023) IN NUCLEOSIDE-NAÏVE PATIENTS
G
Yao. Abstract
519.HIGH BARRIER TO RESISTANCE RESULTS IN NO EMERGENCE OF ENTECAVIR RESISTANCE
IN NUCLEOSIDE-NAÏVE SUBJECTS DURING THE FIRST TWO YEARS OF THERAPY
R J Colonno. Abstract 490. MODELING CLINICAL BENEFITS OF SUPPRESSING VIRAL REPLICATION IN HBEAG-NEGATIVE
CHRONIC HEPATITIS B (CHB) PATIENTS: A NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS OF
ENTECAVIR AND ADEFOVIR
U H Iloeje.
Abstract 497.EFFECTS OF ENTECAVIR AND LAMIVUDINE ON ADVANCED LIVER FIBROSIS AFTER
48 WEEKS OF TREATMENT IN PATIENTS WITH CHB INFECTION: RESULTS OF THREE PIVOTAL
TRIALS
H
Simsek. Abstract 513. ENTECAVIR (ETV) DEMONSTRATES CONSISTENT RESPONSES THROUGHOUT BASELINE
DISEASE AND DEMOGRAPHIC SUBGROUPS FOR THE TREATMENT OF LAMIVUDINE-REFRACTORY HBEAG(+)
PATIENTS WITH CHRONIC HEPATITIS B
C Youdaydin. Abstract 512.
Peginterferon
alfa-2a (Pegasys)
THE
MAJORITY OF PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON
ALFA-2A (40KD) [PEGASYS®] SUSTAIN RESPONSES 2 YEARS POST-TREATMENT
P Marcellin. Abstract 743.
PEGINTERFERON
ALFA-2A (40KD) (PEGASYS) REVERSES CIRRHOSIS, IMPROVES FIBROSIS AND SLOWS PROGRESSION
OF FIBROSIS IN PATIENTS WITH HBEAG-POSITIVE OR HBEAG-NEGATIVE CHRONIC HEPATITIS
B (CHB).
G Cooksley.
Abstract 491. EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) IN PATIENTS
WITH CHRONIC HEPATITIS B WHO HAD RECEIVED PRIOR TREATMENT WITH NUCLEOS(T)IDE ANALOGUES
– THE PEGALAM COHORT
P
Marcellin. Abstract 502.
HBEAG AND HBV DNA KINETICS IN HBSAG CLEARANCE WITH PEGINTERFERON ALFA-2A
(40KD) (PEGASYS) TREATMENT FOR HBEAG-POSITIVE CHRONIC HEPATITIS B (CHB)
M W
Fried. Abstract 492.
Lamivudine
(Epivir-HBV)
Format
EMERGENCE
OF DUAL-RESISTANCE HBV MUTATIONS TO ADEFOVIR-DIPIVOXIL AND LAMIVUDINE IN
A HEPATITIS B PATIENT WITH COMBINATION THERAPY FOR ADEFOVIR-RESISTANCE
SY
Kwon. Abstract 740. LAMIVUDINE THERAPY IN CHILDREN WITH CHRONIC HEPATITIS B.
A
Liberek. Abstract 501.
EARLY HEPATITIS B VIRAL DYNAMICS AND END OF TREATMENT VIROLOGICAL
RESPONSE (ETVR) IN CHRONIC HEPATITIS B/ HBEAG (-) PATIENTS RECEIVING PEGYLATED
INTERFERON ALFA-2B AND/OR LAMIVUDINE.
T Vassiliadis. Abstract 517.TREATMENT
WITH ADEFOVIR ALONE OR IN COMBINATION WITH LAMIVUDINE IN CHRONIC HEPATITIS B LAMIVUDINE-RESISTANT
PATIENTS: RESULTS AFTER TWO YEARS.
V
Barbon. Abstract 480. HBV QUASISPECIES SELECTED DURING LAMIVUDINE TREATMENT MAY CONTRIBUTE
TO ADEFOVIR DIPIVOXIL RESISTANCE
F
Moriconi. Abstract 504.
| 
